APLLTD Stoklara Genel Bakış Alembic Pharmaceuticals Limited, Hindistan'da ve uluslararası alanda farmasötik ürünler geliştirmekte, üretmekte ve pazarlamaktadır. Daha fazla detay
Ödüller Risk Analizi Tüm Risk Kontrollerini Gör Düşüncelerinizi, bağlantılarınızı ve şirket anlatımınızı yakalayın
Alembic Pharmaceuticals Limited Rakipler Fiyat Geçmişi ve Performans
Hisse fiyatlarındaki yükseliş, düşüş ve değişimlerin özeti Alembic Pharmaceuticals Tarihsel hisse senedi fiyatları Güncel Hisse Fiyatı ₹1,055.15 52 Haftanın En Yüksek Seviyesi ₹1,303.90 52 Haftanın En Düşük Seviyesi ₹746.50 Beta 0.71 1 Aylık Değişim 1.28% 3 Aylık Değişim -9.44% 1 Yıllık Değişim 36.47% 3 Yıllık Değişim 37.35% 5 Yıllık Değişim 86.54% Halka arzdan bu yana değişim 2,109.74%
Son Haberler & Güncellemeler
Alembic Pharmaceuticals Limited Announces USFDA Tentative Approval for Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% Dec 05
Earnings Miss: Alembic Pharmaceuticals Limited Missed EPS By 5.6% And Analysts Are Revising Their Forecasts Nov 10
Second quarter 2025 earnings: EPS and revenues miss analyst expectations Nov 08
Alembic Pharmaceuticals Limited Announces Superannuation of Vipul Gandhi, Head - Business Development - Formulations Nov 07
Alembic Pharmaceuticals Limited Receives Final Approval from the US Food & Drug Administration for its Abbreviated New Drug Application Diltiazem Hydrochloride Extended-Release Capsules Oct 21
Alembic Pharmaceuticals Limited to Report Q2, 2025 Results on Nov 07, 2024 Oct 18 Daha fazla güncelleme görün
Alembic Pharmaceuticals Limited Announces USFDA Tentative Approval for Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% Dec 05
Earnings Miss: Alembic Pharmaceuticals Limited Missed EPS By 5.6% And Analysts Are Revising Their Forecasts Nov 10
Second quarter 2025 earnings: EPS and revenues miss analyst expectations Nov 08
Alembic Pharmaceuticals Limited Announces Superannuation of Vipul Gandhi, Head - Business Development - Formulations Nov 07
Alembic Pharmaceuticals Limited Receives Final Approval from the US Food & Drug Administration for its Abbreviated New Drug Application Diltiazem Hydrochloride Extended-Release Capsules Oct 21
Alembic Pharmaceuticals Limited to Report Q2, 2025 Results on Nov 07, 2024 Oct 18
Now 21% overvalued after recent price rise Oct 15
Alembic Pharmaceuticals Limited Announces USFDAFinal Approval for Lamotrigine Extended-Release Tablets Usp, 200 mg, 250 mg, and 300 mg Oct 06
Alembic Pharmaceuticals Limited's (NSE:APLLTD) Intrinsic Value Is Potentially 17% Below Its Share Price Sep 25
Alembic Pharmaceuticals Limited Appoints Mr. Sudhakar Pandiyan as Head - Technical Operations Sep 16
Investor sentiment improves as stock rises 17% Sep 10
Price target increased by 7.2% to ₹1,056 Sep 10
Now 25% overvalued after recent price rise Sep 09
Is Alembic Pharmaceuticals (NSE:APLLTD) Using Too Much Debt? Sep 03
Alembic Pharmaceuticals Limited Receives Final Approval from the US Food & Drug Administration for Its Abbreviated New Drug Application Betamethasone Valerate Foam, 0.12% Aug 24
Alembic Pharmaceuticals Limited Announces Resignation of Nilesh Shah as Head Legal Aug 22
Alembic Pharmaceuticals Limited Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now Aug 13
First quarter 2025 earnings: EPS and revenues miss analyst expectations Aug 09
Alembic Pharmaceuticals Limited to Report Q1, 2025 Results on Aug 08, 2024 Jul 25
Alembic Pharmaceuticals Receives USFDA Final Approval for Fluphenazine Hydrochloride Tablets USP, 1 Mg, 2.5 Mg, 5 Mg, and 10 Mg Jul 24
Market Participants Recognise Alembic Pharmaceuticals Limited's (NSE:APLLTD) Earnings Pushing Shares 25% Higher Jul 20
Alembic Pharmaceuticals Limited Announces USFDA Tentative Approval for Selexipag for Injection, 1,800 Mc/Vial Jul 12
Alembic Pharmaceuticals Announces Usfda Final Approval for Bromfenac Ophthalmic Solution, 0.07% Jul 09
Upcoming dividend of ₹11.00 per share Jul 08
Alembic Pharmaceuticals Limited Receives USFDATentative Approval for Ivosidenib Tablets 250 Mg Jul 04
Now 21% overvalued Jul 01
Full year 2024 earnings: EPS exceeds analyst expectations while revenues lag behind Jun 25
Dividend increased to ₹11.00 Jun 24
Alembic Pharmaceuticals Limited, Annual General Meeting, Jul 22, 2024 Jun 10
Alembic Pharmaceuticals Limited Announces Superannuation of Chandrahas Shetty as President-Human Resources (India Branded Business) Jun 08
Alembic Pharmaceuticals (NSE:APLLTD) Seems To Use Debt Rather Sparingly Jun 03
Now 20% overvalued May 29
Does This Valuation Of Alembic Pharmaceuticals Limited (NSE:APLLTD) Imply Investors Are Overpaying? May 11
Full year 2024 earnings released: EPS: ₹31.33 (vs ₹17.40 in FY 2023) May 10 Alembic Pharmaceuticals Limited Receives Various US Food & Drug Administration (Tentative or Final) Product Approvals
Alembic Pharmaceuticals Limited to Report Q4, 2024 Results on May 09, 2024 Apr 20
Price target increased by 8.4% to ₹933 Apr 12
Consensus EPS estimates increase by 14% Feb 12
Results: Alembic Pharmaceuticals Limited Exceeded Expectations And The Consensus Has Updated Its Estimates Feb 08
Price target increased by 7.4% to ₹827 Feb 07
Third quarter 2024 earnings: Revenues in line with analyst expectations Feb 06
Subdued Growth No Barrier To Alembic Pharmaceuticals Limited (NSE:APLLTD) With Shares Advancing 25% Jan 21
Alembic Pharmaceuticals Limited to Report Q3, 2024 Results on Feb 05, 2024 Jan 19
Investor sentiment improves as stock rises 17% Jan 15
Is Alembic Pharmaceuticals (NSE:APLLTD) A Risky Investment? Jan 05 Alembic Pharmaceuticals Receives Various Us Food & Drug Administration Product Approvals
Alembic Pharmaceuticals Limited Appoints Pradeep Chakravarty as Head - Global Quality Dec 04
Alembic Pharmaceuticals Limited Announces Management Changes Nov 29
Alembic Pharmaceuticals Limited Announces Management Changes Nov 28
Alembic Pharmaceuticals Limited to Report Q2, 2024 Results on Nov 07, 2023 Oct 17
Here's Why Alembic Pharmaceuticals (NSE:APLLTD) Can Manage Its Debt Responsibly Sep 27
Alembic Pharmaceuticals Limited Announces Resignation of Jesal Shah as Head - Strategy Sep 02
Alembic Pharmaceuticals Limited Announces That Mr. Nilesh Wadhwa, Head - International Business & Strategy (Formulations Business Development Division), Is Designated as Senior Management Personnel Aug 22
Price target increased by 10% to ₹659 Aug 07
First quarter 2024 earnings released: EPS: ₹6.14 (vs ₹3.35 loss in 1Q 2023) Aug 05
Alembic Pharmaceuticals Limited to Report Q1, 2024 Results on Aug 04, 2023 Jul 24
Upcoming dividend of ₹8.00 per share at 1.2% yield Jul 21
Full year 2023 earnings: EPS exceeds analyst expectations Jun 24
Alembic Pharmaceuticals (NSE:APLLTD) Seems To Use Debt Quite Sensibly Jun 09
Alembic Pharmaceuticals Limited, Annual General Meeting, Aug 04, 2023 Jun 06
Full year 2023 earnings: EPS exceeds analyst expectations May 07 Alembic Pharmaceuticals Limited Approves the Appointment of Jai Diwanji as an Independent Director
A Look At The Fair Value Of Alembic Pharmaceuticals Limited (NSE:APLLTD) Apr 13
Is Alembic Pharmaceuticals (NSE:APLLTD) A Risky Investment? Feb 22
Consensus EPS estimates fall by 19% Feb 10
Third quarter 2023 earnings released: EPS: ₹6.20 (vs ₹8.98 in 3Q 2022) Feb 04
Consensus EPS estimates fall by 11% Feb 03
Alembic Pharmaceuticals Limited Announces Company Secretary and Compliance Officer Changes Feb 02
Alembic Pharmaceuticals Receives USFDA Tentative Approval for Acalabrutinib Capsules, 100 Mg Jan 20
Alembic Pharmaceuticals Limited Receives Final Approval from the US Food & Drug Administration Jan 07
Alembic Pharmaceuticals Limited (NSE:APLLTD) Shares Could Be 21% Below Their Intrinsic Value Estimate Jan 04
Now 20% undervalued after recent price drop Dec 20
Alembic Pharmaceuticals Limited Receives USFDA Final Approval for DesonideCream, 0.05% Dec 11
Alembic Pharmaceuticals Receives USFDA Final Approval for Diclofenac Sodium Topical Solution USP, 2% w/w Dec 01
Alembic Pharmaceuticals Receives USFDA Final Approval for Nifedipine Extended-Release Tablets USP, 30 Mg, 60 Mg and 90 Mg Nov 21
Consensus forecasts updated Nov 18
Insufficient new directors Nov 16
Alembic Pharmaceuticals Limited Receives US FDA Final Approval for Cyclophosphamide Capsules, 25 Mg and 50 Mg Nov 15
Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind Nov 13
We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Alembic Pharmaceuticals Limited's (NSE:APLLTD) CEO For Now Nov 05
Investor sentiment improved over the past week Nov 03
Alembic Pharmaceuticals Receives Usfda Final Approval for Mesalamine Extended-Release Capsules Usp, 0.375 G Nov 03
Alembic Pharmaceuticals Limited to Report Q2, 2023 Results on Nov 11, 2022 Nov 02
Alembic Pharmaceuticals Limited (Alembic) Receives Final Approval from the Us Food & Drug Administration Oct 29
Alembic Pharmaceuticals Limited Announces Successful Completion of USFDA Inspection at Alembic Pharmaceuticals' Bioequivalence Facility at Vadodara Oct 27
Alembic Pharmaceuticals Limited, Annual General Meeting, Nov 11, 2022 Sep 16
Alembic Pharmaceuticals Limited Receives; U.S. Food & Drug Administration Final Approval for Chlorthalidone Tablets USP, 25 Mg and 50 Mg Aug 29
Consensus EPS estimates fall by 28% Aug 11
Upcoming dividend of ₹10.00 per share Aug 10
Here's Why Alembic Pharmaceuticals (NSE:APLLTD) Has A Meaningful Debt Burden Aug 10
Price target decreased to ₹734 Aug 07
First quarter 2023 earnings released: ₹3.35 loss per share (vs ₹8.37 profit in 1Q 2022) Aug 05
Alembic Pharmaceuticals Limited to Report Q1, 2023 Results on Aug 04, 2022 Jul 21
Estimating The Intrinsic Value Of Alembic Pharmaceuticals Limited (NSE:APLLTD) Jul 20
Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind Jun 22
Alembic Pharmaceuticals Receives US Food & Drug Administration Tentative Approval for Dasatinib Tablets, 20 Mg, 50 Mg, 70 Mg, 80 Mg, 100 Mg, and 140 Mg Jun 11 Hissedar Getirileri APLLTD IN Pharmaceuticals IN Pazar 7D -0.6% 0.8% -4.2% 1Y 36.5% 39.7% 19.1%
Hissedar getirilerinin tamamını görün
Getiri vs. Endüstri: APLLTD geçen yıl % 39.7 oranında getiri sağlayan Indian Pharmaceuticals sektörünün gerisinde kaldı.
Getiri vs Piyasa: APLLTD geçen yıl % 19.1 oranında getiri sağlayan Indian Piyasasını aştı.
Fiyat Oynaklığı Is APLLTD's price volatile compared to industry and market? APLLTD volatility APLLTD Average Weekly Movement 4.7% Pharmaceuticals Industry Average Movement 6.0% Market Average Movement 6.2% 10% most volatile stocks in IN Market 9.0% 10% least volatile stocks in IN Market 4.1%
İstikrarlı Hisse Senedi Fiyatı: APLLTD son 3 ayda önemli bir fiyat oynaklığı yaşamadı.
Zaman İçindeki Volatilite: APLLTD 'nin haftalık oynaklığı ( 5% ) son bir yıldır istikrarlı seyretti.
Şirket Hakkında Alembic Pharmaceuticals Limited, Hindistan'da ve uluslararası alanda farmasötik ürünler geliştirmekte, üretmekte ve pazarlamaktadır. Şirket, kardiyoloji, jinekoloji, gastroloji, oftalmoloji, dermatoloji, nefroloji/üroloji, ortopedi, anti-enfektif, soğuk algınlığı ve öksürük, veterinerlik ve anti-diyabetik gibi çeşitli terapötik alanlarda markalı özel ilaçlar; oral katılar, onkoloji oral katılar ve enjektabllar, genel enjektabllar ve oftalmik ürünler, dermatoloji ve oral süspansiyonda jenerik formülasyonlar ve aktif farmasötik bileşenler sunmaktadır. Ayrıca ürünlerini ihraç etmektedir.
Daha fazla göster Alembic Pharmaceuticals Limited Temel Bilgiler Özeti Alembic Pharmaceuticals'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır? APLLTD temel i̇stati̇sti̇kler Piyasa değeri ₹207.40b Kazançlar(TTM ) ₹6.47b Gelir(TTM ) ₹63.57b
Kazanç ve Gelir En son kazanç raporundan temel karlılık istatistikleri (TTM) APLLTD gelir tablosu (TTM ) Gelir ₹63.57b Gelir Maliyeti ₹17.44b Brüt Kâr ₹46.13b Diğer Giderler ₹39.66b Kazançlar ₹6.47b
Son Raporlanan Kazançlar
Sep 30, 2024
Hisse başına kazanç (EPS) 32.90 Brüt Marj 72.56% Net Kâr Marjı 10.17% Borç/Özkaynak Oranı 20.4%
APLLTD uzun vadede nasıl bir performans gösterdi?
Geçmiş performansı ve karşılaştırmayı görün Temettüler
1.0% Mevcut Temettü Verimi
Şirket Analizi ve Finansal Veri Durumu Veri Son Güncelleme (UTC saati) Şirket Analizi 2024/12/22 08:11 Gün Sonu Hisse Fiyatı 2024/12/20 00:00 Kazançlar 2024/09/30 Yıllık Kazançlar 2024/03/31
Veri Kaynakları Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC 'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
Paket Veri Zaman Çerçevesi Örnek ABD Kaynağı * Şirket Finansalları 10 yıl Gelir tablosu Nakit akış tablosu Bilanço Analist Konsensüs Tahminleri +3 yıl Finansal tahminler Analist fiyat hedefleri Piyasa Fiyatları 30 yıl Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler Sahiplik 10 yıl En büyük hissedarlar İçeriden öğrenenlerin ticareti Yönetim 10 yıl Liderlik ekibi Yönetim Kurulu Önemli Gelişmeler 10 yıl
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Buradan daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube' da eğitimlerimiz bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları 'da mevcuttur.
Analist Kaynakları Alembic Pharmaceuticals Limited 26 Bu analistlerden 11, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
Analist Kurum Sarabjit Nangra Angel Broking Private Limited null null Antique Stockbroking Ltd. Vijayaraghavan Swaminathan Avendus Spark
Göster 23 daha fazla analist 
